Open-label, randomised multicentre study of CAMPATH-1H versus basiliximab induction treatment and sirolimus versus tacrolimus maintenance treatment for the preservation of renal function in patients receiving kidney transplants.

Trial Profile

Open-label, randomised multicentre study of CAMPATH-1H versus basiliximab induction treatment and sirolimus versus tacrolimus maintenance treatment for the preservation of renal function in patients receiving kidney transplants.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Sirolimus (Primary) ; Basiliximab; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms 3C
  • Most Recent Events

    • 03 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2019.
    • 30 Jan 2014 According to ClinicalTrials.gov record planned end date changed from 1 Dec 2039 to 1 Feb 2017.
    • 27 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top